Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Malignant Lymphoma

  Free Subscription


Articles published in Br J Dermatol

Retrieve available abstracts of 43 articles:
HTML format



Single Articles


    June 2022
  1. BATTESTI G, Ram-Wolff C, Dobos G, Aubin F, et al
    Granulomatous slack skin: clinical characteristics, prognosis, and response to therapy. A study from the Cutaneous Lymphoma French Study Group.
    Br J Dermatol. 2022 Jun 6. doi: 10.1111/bjd.21699.
    PubMed    


  2. ROELENS M, de Masson A, Andrillon A, Ram-Wolff C, et al
    Mogamulizumab induces long-term immune restoration and reshapes tumour heterogeneity in Sezary syndrome.
    Br J Dermatol. 2022;186:1010-1025.
    PubMed     Abstract available


    May 2022
  3. MITTELDORF C
    Multistaining for a better understanding of lymphoma biology.
    Br J Dermatol. 2022 May 4. doi: 10.1111/bjd.21590.
    PubMed    


    March 2022
  4. DOBOS G, Assaf C
    Transcriptomic changes during stage progression of mycosis fungoides: from translational analyses to their potential clinical implications.
    Br J Dermatol. 2022;186:387-388.
    PubMed    


  5. XIAO MZX, Hennessey D, Iyer A, O'Keefe S, et al
    Transcriptomic changes during stage progression of mycosis fungoides.
    Br J Dermatol. 2022;186:520-531.
    PubMed     Abstract available


    February 2022
  6. VERMEER MH, Moins-Teisserenc H, Bagot M, Quaglino P, et al
    Flow cytometry for the assessment of blood tumour burden in cutaneous T-cell lymphoma: towards a standardised approach.
    Br J Dermatol. 2022 Feb 14. doi: 10.1111/bjd.21053.
    PubMed     Abstract available


  7. FALKENHAIN-LOPEZ D, Fulgencio-Barbarin J, Puerta-Pena M, Montero-Menarguez J, et al
    Single-centre experience of using pegylated liposomal doxorubicin as maintenance treatment in mycosis fungoides.
    Br J Dermatol. 2022;186:363-365.
    PubMed    


    January 2022
  8. KEMPF W, Petrella T, Willemze R, Jansen P, et al
    Clinical, histopathological and prognostic features of primary cutaneous acral CD8+ T-cell lymphoma and other dermal CD8+ cutaneous lymphoproliferations - Results of an EORTC Cutaneous Lymphoma Group Workshop.
    Br J Dermatol. 2022 Jan 5. doi: 10.1111/bjd.20973.
    PubMed     Abstract available


  9. BLANCHARD G, Guenova E
    Mogamulizumab-associated rash (MAR) mars its efficacy in the treatment of cutaneous lymphoma.
    Br J Dermatol. 2022;186:15-16.
    PubMed    


    November 2021
  10. PAPADAVID E, Kapniari E, Pappa V, Nikolaou V, et al
    Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sezary syndrome with variable CD30 positivity.
    Br J Dermatol. 2021;185:1035-1044.
    PubMed     Abstract available


  11. MOYAL L, Arkin C, Gorovitz-Haris B, Querfeld C, et al
    Mycosis fungoides-derived exosomes promote cell motility and are enriched with microRNA-155 and microRNA-1246, and their plasma-cell-free expression may serve as a potential biomarker for disease burden.
    Br J Dermatol. 2021;185:999-1012.
    PubMed     Abstract available


    October 2021
  12. HENDERSON BERG MH, Davison K, Popradi G
    Real-world effectiveness of brentuximab vedotin in the treatment of CD30-positive cutaneous T-cell lymphoma: A single-centre retrospective review.
    Br J Dermatol. 2021 Oct 5. doi: 10.1111/bjd.20786.
    PubMed     Abstract available


    September 2021
  13. POSPISCHIL I, Guenova E
    Mycosis fungoides-derived exosomes and their microRNA-1246 cargo: a message from the skin.
    Br J Dermatol. 2021 Sep 14. doi: 10.1111/bjd.20695.
    PubMed    


    August 2021
  14. TRUM NA, Zain J, Martinez XU, Parekh V, et al
    Mogamulizumab Efficacy is Underscored by its Associated Rash that Mimics Cutaneous T-cell Lymphoma: A Retrospective Single-Centre Case Series.
    Br J Dermatol. 2021 Aug 24. doi: 10.1111/bjd.20708.
    PubMed     Abstract available


  15. HODAK E
    Is lymph node core-needle biopsy an alternative to excisional biopsy for the accurate staging of mycosis fungoides/Sezary syndrome and predicting the survival of patients?
    Br J Dermatol. 2021;185:251-252.
    PubMed    


  16. ORTIZ-ROMERO PL
    The time for new biomarkers in mycosis fungoides/Sezary syndrome is here.
    Br J Dermatol. 2021;185:250-251.
    PubMed    


  17. OTTEVANGER R, de Bruin DT, Willemze R, Jansen PM, et al
    Incidence of mycosis fungoides and Sezary syndrome in the Netherlands between 2000 and 2020.
    Br J Dermatol. 2021;185:434-435.
    PubMed    


  18. CALVANI J, de Masson A, de Margerie-Mellon C, de Kerviler E, et al
    Image-guided lymph node core-needle biopsy predicts survival in mycosis fungoides and Sezary syndrome.
    Br J Dermatol. 2021;185:419-427.
    PubMed     Abstract available


  19. DOBOS G, De Cevins C, Ly Ka So S, Jean-Louis F, et al
    The value of five blood markers in differentiating mycosis fungoides and Sezary syndrome: a validation cohort.
    Br J Dermatol. 2021;185:405-411.
    PubMed     Abstract available


    July 2021
  20. GAMBICHLER T, Boms S, Hessam S, Tischoff I, et al
    Primary cutaneous anaplastic large cell lymphoma with marked spontaneous regression of organ manifestation after SARS-CoV-2 vaccination.
    Br J Dermatol. 2021 Jul 6. doi: 10.1111/bjd.20630.
    PubMed     Abstract available


    June 2021
  21. SKAYEM C, Beylot-Barry M, de Masson A, Dereure O, et al
    Lymph node and visceral progression without erythroderma or blood worsening in erythrodermic cutaneous T-cell lymphoma: nine cases.
    Br J Dermatol. 2021 Jun 15. doi: 10.1111/bjd.20580.
    PubMed     Abstract available


    May 2021
  22. JONAK C, Alkon N, Rindler K, Rojahn TB, et al
    Single-cell RNAseq profiling in a patient with discordant primary cutaneous B and T cell lymphoma reveals micromilieu-driven immune skewing.
    Br J Dermatol. 2021 May 21. doi: 10.1111/bjd.20512.
    PubMed     Abstract available


  23. ZIMMERMANN C, Boisson M, Ram-Wolff C, Sadoux A, et al
    Diagnostic performance of high throughput sequencing of the T-cell receptor beta gene for the diagnosis of cutaneous T-cell lymphoma.
    Br J Dermatol. 2021 May 3. doi: 10.1111/bjd.20432.
    PubMed     Abstract available


  24. MOLLOY K, Vico C, Ortiz-Romero PL, Scarisbrick JJ, et al
    Real-world experience of using mogamulizumab in relapsed/refractory mycosis fungoides/Sezary syndrome.
    Br J Dermatol. 2021;184:978-981.
    PubMed    


    April 2021
  25. PORCU P, Nikbakht N
    New insights on treatment utilization and outcomes in early-stage mycosis fungoides.
    Br J Dermatol. 2021;184:594-595.
    PubMed    


    March 2021
  26. VERMEER M
    Epidemiology of cutaneous lymphoma.
    Br J Dermatol. 2021 Mar 3. doi: 10.1111/bjd.19829.
    PubMed    


  27. HODAK E, Sherman S, Papadavid E, Bagot M, et al
    Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study.
    Br J Dermatol. 2021;184:524-531.
    PubMed     Abstract available


    February 2021
  28. WINGE MCG, Iberri DJ, Novoa RA, Kwong BY, et al
    Telescope punch biopsy of normal-appearing skin to diagnose intravascular lymphoma.
    Br J Dermatol. 2021 Feb 1. doi: 10.1111/bjd.19711.
    PubMed    


    January 2021
  29. WEHKAMP U, Mitteldorf C, Stendel S, Stranzenbach R, et al
    Most rare subtypes of cutaneous lymphoma display variable CD30 expression. Analysis of the German Cutaneous Lymphoma Network.
    Br J Dermatol. 2021 Jan 22. doi: 10.1111/bjd.19823.
    PubMed     Abstract available


    November 2020
  30. VERMEER MH, Nicolay JP, Scarisbrick JJ, Zinzani PL, et al
    The importance of assessing blood tumour burden in cutaneous T-cell lymphoma.
    Br J Dermatol. 2020 Nov 6. doi: 10.1111/bjd.19669.
    PubMed     Abstract available


    October 2020
  31. DOBOS G, de Masson A, Ram-Wolff C, Beylot-Barry M, et al
    Epidemiological changes in cutaneous lymphomas: an analysis of 8,593 patients from the French Cutaneous Lymphoma Registry.
    Br J Dermatol. 2020 Oct 31. doi: 10.1111/bjd.19644.
    PubMed     Abstract available


    September 2020
  32. GABES M
    Are existing quality-of-life instruments in cutaneous T-cell lymphoma of sufficient quality?
    Br J Dermatol. 2020 Sep 1. doi: 10.1111/bjd.19408.
    PubMed    


    August 2020
  33. D'INCAN M, Ingen-Housz-Oro S, Beylot-Barry M, Joly P, et al
    Locoregional nodal extension does not impair prognosis of primary cutaneous anaplastic lymphomas.
    Br J Dermatol. 2020 Aug 18. doi: 10.1111/bjd.19495.
    PubMed     Abstract available


  34. CHIRICO A, Henderson Berg MH, Roberge D, Pehr K, et al
    Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphoma.
    Br J Dermatol. 2020 Aug 15. doi: 10.1111/bjd.19490.
    PubMed     Abstract available


  35. TOUSSAINT F, Erdmann M, Grosch E, Schliep S, et al
    Transient response to nivolumab and relapse after infliximab in a patient with primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma.
    Br J Dermatol. 2020 Aug 7. doi: 10.1111/bjd.19470.
    PubMed     Abstract available


    July 2020
  36. MIRZA FN, Yumeen S, Girardi M
    Disparities in Outcomes of CD8(+) Cutaneous T Cell Lymphoma by Race and Presenting Lesion Location.
    Br J Dermatol. 2020 Jul 30. doi: 10.1111/bjd.19426.
    PubMed     Abstract available


    June 2020
  37. BHAT TS, Herbosa CM, Rosenberg AR, Sogade O, et al
    Current measures are not sufficient: an interview-based qualitative assessment of quality of life in cutaneous T-cell lymphoma.
    Br J Dermatol. 2020 Jun 8. doi: 10.1111/bjd.19298.
    PubMed     Abstract available


  38. QUAGLINO P, Prince HM, Cowan R, Vermeer M, et al
    Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Study (PROCLIPI study).
    Br J Dermatol. 2020 Jun 1. doi: 10.1111/bjd.19252.
    PubMed     Abstract available


    May 2020
  39. DANGIEN A, Ram-Wolff C, Brice P, Battistella M, et al
    Ifosfamide and etoposide in advanced-stage, relapsed or refractory primary cutaneous T-cell lymphomas.
    Br J Dermatol. 2020 May 14. doi: 10.1111/bjd.19220.
    PubMed     Abstract available


    February 2020
  40. HWANG S, Johnson A, Fabbro S, Hastings J, et al
    Topical imiquimod monotherapy for indolent primary cutaneous B-cell lymphomas (PCBCL): a single-institution experience.
    Br J Dermatol. 2020 Feb 20. doi: 10.1111/bjd.18961.
    PubMed     Abstract available


    December 2019
  41. TALPUR R
    Quality of life, Skindex-29, mycosis fungoides/Sezary syndrome.
    Br J Dermatol. 2019 Dec 11. doi: 10.1111/bjd.18710.
    PubMed    


    June 2019
  42. DUMONT M, Ram-Wolff C, Roelens M, Brice P, et al
    Efficacy and safety of brentuximab vedotin plus bendamustine in advanced-stage primary cutaneous T-cell lymphomas.
    Br J Dermatol. 2019 Jun 17. doi: 10.1111/bjd.18215.
    PubMed     Abstract available


    March 2019
  43. DEQUIDT L, Franck N, Sanchez-Pena P, Dalle S, et al
    Cutaneous lymphomas appearing under biologics: 44 cases from the French Study Group on Cutaneous Lymphomas and French Pharmacovigilance Database.
    Br J Dermatol. 2019 Mar 5. doi: 10.1111/bjd.17834.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: